abatacept IV
Selected indexed studies
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (Ann Rheum Dis, 2023) [PMID:36357155]
- Abatacept: A Review in Rheumatoid Arthritis. (Drugs, 2017) [PMID:28608166]
- 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. (Ann Rheum Dis, 2024) [PMID:39739385]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Abatacept for the treatment of rheumatoid arthritis. (2019) pubmed
- Abatacept and the risk of malignancy: a meta-analysis across disease indications. (2025) pubmed
- Abatacept: A Review in Rheumatoid Arthritis. (2017) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (2023) pubmed
- 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. (2024) pubmed
- Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial. (2025) pubmed
- FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD. (2025) pubmed
- Practice guidelines for the use of subcutaneous abatacept. (2014) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. (2026) pubmed
- Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. (2020) pubmed